(Q36491829)

14 August 2017

1 reference

title

New antiepileptic drugs that are second generation to existing antiepileptic drugs (English)

1 reference

14 August 2017

Meir Bialer

1

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

Expert Opinion on Investigational Drugs

14 August 2017

published in

1 reference

14 August 2017

volume

15

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

637-647

1 reference

Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII)

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Pros and cons for the development of new antiepileptic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

The new antiepileptic drugs: pharmacological and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

New antiepileptic drugs currently in clinical trials: is there a strategy in their development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Safety, tolerability and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic agent, during first administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Safety, tolerability, and pharmacokinetic profile of BIA 2-093, a novel putative antiepileptic, in a rising multiple-dose study in young healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(-)-10,11-dihydro-10-hydroxy carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Differentiation between valproate-induced anticonvulsant effect, teratogenicity and hepatotoxicity. Aspects of species variation, pharmacokinetics, metabolism and implications of structural specificity for the development of alternative antiepilepti

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Valproic Acid-Induced Neural Tube Defects in Mouse and Human: Aspects of Chirality, Alternative Drug Development, Pharmacokinetics and Possible Mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

CYP2E1-mediated modulation of valproic acid-induced hepatocytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Clinical pharmacology of valpromide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: a new antiepileptic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Reduction in diabetes-induced craniofacial defects by maternal immune stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Valproate decreases inositol biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Anti-tumor mechanisms of valproate: a novel role for an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Valproate and valproate-analogues: potent tools to fight against cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

ApoE epsilon4 allele and disease duration affect verbal learning in mild temporal lobe epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Anticonvulsant and antiepileptogenic effects of fluorofelbamate in experimental status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

21 January 2018

New anti-epileptic drugs

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

Antiepileptic drug discovery: lessons from the past and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

The first case of invasive EEG monitoring for the surgical treatment of epilepsy: historical significance and context

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.6.637

10.1517/13543784.15.6.637

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference